Pulmatrix Inc (PULM)

[3DYOGI]

The significance of the licensing deal: Validation of its iSperse Technology to support its lead assets: PUR1900 & PUR1800.

http://www.pulmatrix.com


5 X more effective , 15% of $3 Billion = $450 Million or $22.50 EPS. and that's just the US market.


Cystic Fibrosis foundation is a huge deal...


Over 50% of the float is owned by insiders and Inst. Only 20 Million shares outstanding less than 10 million floating...


PULM founders
David Edwards, PhD Professor of Biomedical Engineering, Harvard University
Mark Gabrielson Owner and General Partner, p-Value Capital
Alexander Klibanov, PhD Professor of Chemistry and Bioengineering, MIT
Robert Langer, PhD Professor of Chemical and Biomedical Engineering, MIT


$PULM